Core Viewpoint - The announcement from Ximing Life Science (00474) reveals significant findings regarding its shareholding structure, indicating a high concentration of ownership among a few shareholders, which may impact liquidity and market dynamics [1] Shareholding Structure - As of December 31, 2025, twenty shareholders and their associates collectively held 1.387 billion shares, representing 18.79% of the company's issued share capital [1] - The three major shareholders own 5.31 billion shares, accounting for 71.94% of the issued share capital, leading to a total of 90.73% of shares held by these entities [1] - Only 684 million shares, or 9.27% of the issued share capital, are held by other shareholders, indicating a highly concentrated ownership structure [1] Stock Price Performance - The company's stock price increased from HKD 0.019 on September 10, 2025, to HKD 0.112 by December 31, 2025, marking a 489% rise [1] - On January 12, 2026, the stock closed at HKD 0.118, reflecting a 521% increase compared to the closing price of HKD 0.019 on September 10, 2025 [1]
港证监：信铭生命科技股权高度集中